Is Thymosin Alpha-1 Legal in California?

HealthRX.com

Thymosin alpha-1 is not FDA-approved and has no compounding clearance

Print or save as PDF

Key numbers

  • 4 yes and 17 noFDA advisory committee vote in December 2024 on adding thymosin alpha-1 to the pharmacy listSource: fda.gov, as cited Nov 7, 2026
  • 1.6 mgStrength per vial of the Zadaxin injection sold outside the US; no US-approved dose existsSource: fda.gov, as cited Nov 7, 2026
  • 45.8%Share losing HBeAg at 72 weeks on thymosin alpha-1 plus interferon, in one double-blind trial of 98 adults, versus 28.0% on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • FDA approval / none; no US marketing application found on Drugs@FDA [1]
  • US orphan drug designations / four, which are not approvals [1]
  • FDA list, state-licensed pharmacies / appears in none of the three categories [2]
  • FDA list, outsourcing facilities / category 3, 'nominated without adequate support' [3]
  • FDA advisory committee vote, December 2024 / 4 yes, 17 no [4]
  • HHS October 2026 peptide draft policy / does not include it [5]
  • Approved outside the US / Italy, India, Hong Kong, per FDA [1]

What the federal status is

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide originally isolated from thymosin fraction 5; the synthetic version has the same sequence [1][6]. A Drugs@FDA search found no US marketing application for thymosin alpha-1, and FDA's December 2024 review records four US orphan drug designations, which come from a separate process and are not an approval [1]. The finished injection sold elsewhere is branded Zadaxin, 1.6 mg per vial, and is not interchangeable with bulk peptide powder [1].

FDA lists national authorisations in Italy, where Zadaxin is authorised as an adjuvant to influenza vaccination in immunocompromised people; in India, for chronic hepatitis B in adults 18 and older with compensated liver disease and viral replication; and in Hong Kong [1]. A SciClone 2014 annual report claims approval in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, mostly for hepatitis B and as a vaccine adjuvant, and FDA said it could not independently verify those broader claims [1]. Two reviews by authors tied to the Zadaxin developer put the number of approving countries at more than 35 (2009) and more than 30 (2007) [7][8]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].

Questions worth asking

Choose the questions you want to keep

Where compounding stands

FDA's list for state-licensed pharmacies and physicians, updated 14 May 2026, places thymosin alpha-1 in none of its three categories [2]. On the list for outsourcing facilities, updated 21 March 2025, it is in category 3, 'nominated without adequate support' [3]. It is not in category 1, the one FDA treats with a general policy of no action against compounders when the stated conditions are met [2][3].

A separate FDA table covering substances that may present significant safety risks lists it in the 'nominated but withdrawn' section: it had been in category 2 and came off when the nominators withdrew. FDA's posted concerns remain: significant risk of immunogenicity for certain routes of administration, peptide impurity and characterisation problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [9].

In December 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate, and FDA proposed not adding the peptide to the pharmacy list [4]. It is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [5].

What the trials showed

A 2026 Cochrane review included 10 randomized trials involving 1,349 adults with chronic hepatitis B. It found possibly lower all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) but with very low certainty, and the reviewers said they were not sure thymosin alpha-1 helps [10]. In one double-blind trial of 98 adults, loss of HBeAg at 72 weeks was 45.8% with thymosin alpha-1 plus interferon and 28.0% with placebo plus interferon, a difference that did not reach statistical significance (P=0.067) [11].

What the Zadaxin label says

The Italian label directs 1.6 mg subcutaneously or intramuscularly twice weekly for four weeks from the first vaccination, repeated from week 8 to week 12. It says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1]. No US-approved dose exists [1].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, where does FDA's list for state-licensed pharmacies place thymosin alpha-1?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Is thymosin alpha-1 legal in California?
Thymosin alpha-1 is not FDA-approved [1], and no FDA or HHS action allows it to be compounded. FDA lists it in none of the three categories for state-licensed pharmacies [2] and in category 3 for outsourcing facilities [3]. California state rules are not covered on this page.
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US marketing application for it. Its four US orphan drug designations come from a separate process and are not approvals [1].
Why did FDA's advisers vote against adding it to the pharmacy list?
Members who voted no cited no compelling evidence of clinical effectiveness and safety; some who voted yes said patients should have access. The vote was 4 yes and 17 no, with no abstentions, on both the free base and the acetate [4].
Is thymosin alpha-1 approved outside the United States?
FDA lists Italy, India and Hong Kong [1]. A SciClone 2014 annual report claims wider approval, which FDA said it could not independently verify [1], and two reviews by authors tied to the developer cite more than 35 or more than 30 countries [7][8]. The European Medicines Agency holds only an orphan designation [1].
Does the October 2026 HHS peptide policy cover thymosin alpha-1?
No. That draft policy names six other peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) and not thymosin alpha-1 [5].
What dose appears on the Zadaxin label?
There is no US-approved dose. The Italian label gives 1.6 mg subcutaneously or intramuscularly twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12 [1].
Show all 11 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. U.S. Food and Drug Administration.
  5. Official web page.
  6. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74(2):725-9.
  7. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
  8. Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
  9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  10. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
  11. Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
Evidence overview for Is Thymosin Alpha-1 Legal in California?